Pegozafermin

DB19062InvestigationalProtein Based Therapies

Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia).

Mechanism: Pharmacologically active on Fibroblast growth factor 21
Curator reviewed
Also known as: Bio89-100 (long-acting glycopegylated fibroblast growth factor 21 (fgf21) analogue)
Code names: BIO89-100 · TEV-47948

Resolves to

Compound

UNIIUO870O6MFSCAS2489589-60-6

Targets

Q9NSA1FGF21

What you can answer from here — as of July 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pegozafermin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account